Close Menu

NEW YORK (GenomeWeb) – PredictImmune announced today that it has received £4.3 million ($5.9 million) from the Wellcome Trust to clinically evaluate its biomarker test for Crohn's disease.

PredictImmune's test — which the company expects to commercialize in the US and Europe next year — is designed to measure genetic markers in whole-blood samples in order to predict which Crohn's disease patients are likely to experience a severe, relapsing form of the disease to help personalize their treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.